About Baird Capital

• Founded: 1997

• Headquarters: Milwaukee, Wisconsin, United States

• AUM: Approximately $7bn as of 2024

• Strategy: Middle-market buyout and growth equity, healthcare and industrials

• Leadership: Managing directors include Jeffrey Klaehn and Michael Dowling

Baird Capital has closed a $450m continuation vehicle for Blue Matter Consulting, a life sciences advisory firm the firm acquired in 2020. Ares led the transaction as anchor investor. The CV structure allowed existing limited partners to cash out while providing those who rolled equity an extended hold period for the asset. Blue Matter specializes in commercial strategy for biopharmaceutical companies.

The transaction reflects sustained GP interest in healthcare services assets acquired during the 2019–2021 vintage window, now approaching typical five-to-seven-year fund life end dates. Single-asset CVs in the $400m–$500m range have become a standard liquidity mechanism for firms holding profitable but illiquid portfolio companies. Ares's participation as lead investor signals continued institutional appetite for healthcare consulting businesses, particularly those with recurring pharma client relationships. Baird's decision to extend the hold rather than pursue a trade sale or IPO suggests the firm sees material upside in Blue Matter's growth trajectory, likely tied to biopharma R&D spending trends.

This marks Baird Capital's first publicly disclosed continuation vehicle. The structure is now a go-to tool for mid-market GPs navigating LP liquidity pressure while avoiding forced sale timelines. Worth watching: whether Baird deploys additional CVs across its healthcare portfolio, and whether pricing on this transaction reflects a premium or discount to 2020 entry valuation. Single-asset CVs in healthcare services have traded at 10–15% premiums in recent quarters when anchored by repeat secondaries buyers, according to Jefferies secondary market data.

Source: Secondaries Investor